Biosimilar (English Wikipedia)

Analysis of information sources in references of the Wikipedia article "Biosimilar" in English language version.

refsWebsite

Global rank English rank

180web.archive.org

1^st place

105europa.eu

68^th place

117^th place

61fda.gov

447^th place

338^th place

10nih.gov

4^th place

8doi.org

2^nd place

6who.int

195^th place

302^nd place

3centerforbiosimilars.com

low place

2semanticscholar.org

11^th place

8^th place

2health.gov.au

low place

8,252^nd place

2worldcat.org

5^th place

1senate.gov

758^th place

500^th place

1house.gov

529^th place

314^th place

1bioprocessintl.com

low place

1southcentre.int

low place

1tga.gov.au

3,984^th place

2,622^nd place

1biosimilars-nederland.nl

low place

1gi.org

low place

bioprocessintl.com

Wang X (June 1, 2014). "Higher-Order Structure Comparability: Case Studies of Biosimilar Monoclonal Antibodies". BioProcess International. 12 (6): 32–37. Archived from the original on January 19, 2021. Retrieved August 13, 2014.

biosimilars-nederland.nl

"EU Approved biosimilars by molecule [data arranged from EMA website]" (PDF). Biosimilars Nederland. Archived (PDF) from the original on September 19, 2020. Retrieved June 9, 2020.

centerforbiosimilars.com

"Australian Government Announces Decision on Biosimilar Naming Conventions". The Center For Biosimilars. January 31, 2018. Archived from the original on December 30, 2021. Retrieved December 20, 2021.
Dr Ivo Abraham Column: Not All Quiet on the Biologics Front—Biosimilars, Biobetters, and Bioparallels, 2023, retrieved March 8, 2025
Dr Ivo Abraham Column: Not All Quiet on the Biologics Front—Biosimilars, Biobetters, and Bioparallels, 2023, retrieved March 8, 2025

doi.org

Nick, C (2012). "The US Biosimilars Act: Challenges Facing Regulatory Approval". Pharm Med. 26 (3): 145–152. doi:10.1007/bf03262388. S2CID 14604362.
Lamanna WC, Holzmann J, Cohen HP, Guo X, Schweigler M, Stangler T, et al. (April 2018). "Maintaining consistent quality and clinical performance of biopharmaceuticals". Expert Opinion on Biological Therapy. 18 (4): 369–379. doi:10.1080/14712598.2018.1421169. PMID 29285958.
Warren JB (January 2013). "Generics, chemisimilars and biosimilars: is clinical testing fit for purpose?". British Journal of Clinical Pharmacology. 75 (1): 7–14. doi:10.1111/j.1365-2125.2012.04323.x. PMC 3555041. PMID 22574725.
Declerck PJ (February 2013). "Biosimilar monoclonal antibodies: a science-based regulatory challenge". Expert Opinion on Biological Therapy. 13 (2): 153–6. doi:10.1517/14712598.2012.758710. PMID 23286777.
Ivica, N. A., Young, C. M. (August 19, 2021). "Tracking the CAR-T Revolution: Analysis of Clinical Trials of CAR-T and TCR-T Therapies for the Treatment of Cancer (1997–2020)". Healthcare. 9 (8): 1062. doi:10.3390/healthcare9081062. ISSN 2227-9032. PMC 8392279. PMID 34442199.
Sharma, A., Kumar, N., Kuppermann, B. D., Francesco, B., Loewenstein, A. (July 2019). "Biologics, biosilimars, and biobetters: different terms or different drugs?". Eye. 33 (7): 1032–1034. doi:10.1038/s41433-019-0391-5. ISSN 0950-222X. PMC 6707288.
Fasseeh AN, Elezbawy B, El-Fass KA, GamaI M, Seyam A, Hayek N, et al. (June 2023). "Maximizing the benefits of using biosimilars in Egypt". Journal of Pharmaceutical Policy and Practice. 16 (1): 79. doi:10.1186/s40545-023-00581-w. PMC 10291771. PMID 37365620.
Epstein MS, Ehrenpreis ED, Kulkarni PM (December 2014). "Biosimilars: the need, the challenge, the future: the FDA perspective" (PDF). The American Journal of Gastroenterology. 109 (12): 1856–9. doi:10.1038/ajg.2014.151. PMID 24957160. S2CID 19274464. Archived from the original (PDF) on October 6, 2016. Retrieved September 25, 2016.

europa.eu

ema.europa.eu

"Biosimilars in the EU: Information guide for healthcare professionals" (PDF). European Medicines Agency and the European Commission. 2017. Archived from the original (PDF) on October 15, 2019.
"Biosimilar medicines: Overview". European Medicines Agency (EMA). September 17, 2018. Archived from the original on March 29, 2020. Retrieved April 21, 2020.
Biosimilar medicines: Overview, European Medicines Agency (EMA), 2017, retrieved March 8, 2025
"Biosimilar medicines can be interchanged". European Medicines Agency (EMA) (Press release). September 19, 2022. Archived from the original on September 20, 2022. Retrieved September 19, 2022.
"Humira EPAR". European Medicines Agency (EMA). November 24, 2009. Archived from the original on February 18, 2020. Retrieved March 7, 2024.
"Amgevita EPAR". European Medicines Agency (EMA). April 6, 2017. Archived from the original on December 30, 2019. Retrieved April 21, 2020.
"Amsparity EPAR". European Medicines Agency (EMA). December 9, 2019. Archived from the original on February 18, 2020. Retrieved April 21, 2020.
"Cyltezo EPAR". European Medicines Agency (EMA). November 17, 2017. Archived from the original on August 6, 2020. Retrieved August 27, 2021.
"Halimatoz EPAR". European Medicines Agency (EMA). August 3, 2018. Archived from the original on December 30, 2019. Retrieved April 21, 2020.
"Hefiya EPAR". European Medicines Agency (EMA). August 6, 2018. Archived from the original on October 15, 2019. Retrieved April 21, 2020.
"Hukyndra EPAR". European Medicines Agency (EMA). September 14, 2021. Archived from the original on April 24, 2022. Retrieved April 23, 2022.
"Hulio EPAR". European Medicines Agency (EMA). September 21, 2018. Archived from the original on March 24, 2020. Retrieved April 21, 2020.
"Hyrimoz EPAR". European Medicines Agency (EMA). August 2, 2018. Archived from the original on November 16, 2019. Retrieved April 21, 2020.
"Idacio EPAR". European Medicines Agency (EMA). January 29, 2019. Archived from the original on December 30, 2019. Retrieved April 21, 2020.
"Imraldi EPAR". European Medicines Agency (EMA). August 31, 2017. Archived from the original on March 24, 2020. Retrieved April 21, 2020.
"Kromeya EPAR". European Medicines Agency (EMA). January 29, 2019. Archived from the original on December 30, 2019. Retrieved August 27, 2021.
"Libmyris EPAR". European Medicines Agency (EMA). September 14, 2021. Archived from the original on April 24, 2022. Retrieved April 23, 2022.
"Solymbic EPAR". European Medicines Agency (EMA). April 7, 2017. Archived from the original on June 25, 2019. Retrieved August 27, 2021.
"Trudexa EPAR". European Medicines Agency (EMA). February 15, 2008. Archived from the original on February 18, 2020. Retrieved August 27, 2021.
"Yuflyma EPAR". European Medicines Agency (EMA). December 9, 2020. Archived from the original on August 28, 2021. Retrieved August 27, 2021.
"Avastin EPAR". European Medicines Agency (EMA). September 17, 2009. Archived from the original on March 18, 2020. Retrieved September 11, 2021.
"Abevmy EPAR". European Medicines Agency (EMA). February 24, 2021. Archived from the original on August 28, 2021. Retrieved August 27, 2021.
"Alymsys EPAR". European Medicines Agency (EMA). January 25, 2021. Archived from the original on October 8, 2021. Retrieved September 11, 2021.
"Aybintio EPAR". European Medicines Agency (EMA). May 26, 2020. Archived from the original on December 29, 2020. Retrieved September 9, 2020.
"Equidacent EPAR". European Medicines Agency (EMA). July 20, 2020. Archived from the original on October 13, 2020. Retrieved October 12, 2020.
"Mvasi EPAR". European Medicines Agency (EMA). January 31, 2018. Archived from the original on December 30, 2019. Retrieved April 2, 2020.
"Onbevzi EPAR". European Medicines Agency (EMA). November 9, 2020. Archived from the original on November 5, 2021. Retrieved September 11, 2021.
"Oyavas EPAR". European Medicines Agency (EMA). January 25, 2021. Archived from the original on October 8, 2021. Retrieved September 11, 2021.
"Vegzelma EPAR". European Medicines Agency (EMA). June 20, 2022. Archived from the original on January 28, 2023. Retrieved March 3, 2023.
"Zirabev EPAR". European Medicines Agency (EMA). December 11, 2018. Archived from the original on December 30, 2019. Retrieved April 2, 2020.
"Inhixa EPAR". European Medicines Agency (EMA). October 26, 2016. Archived from the original on October 29, 2020. Retrieved September 9, 2020.
"Thorinane EPAR". European Medicines Agency (EMA). October 26, 2016. Archived from the original on December 30, 2019. Retrieved April 2, 2020.
"Abseamed EPAR". European Medicines Agency (EMA). February 6, 2009. Archived from the original on March 23, 2020. Retrieved April 4, 2022.
"Binocrit EPAR". European Medicines Agency (EMA). October 12, 2009. Archived from the original on December 30, 2019. Retrieved April 4, 2022.
"Epoetin Alfa Hexal EPAR". European Medicines Agency (EMA). October 12, 2009. Archived from the original on December 30, 2019. Retrieved April 4, 2022.
"Retacrit EPAR". European Medicines Agency (EMA). January 15, 2008. Archived from the original on December 30, 2019. Retrieved April 4, 2022.
"Silapo EPAR". European Medicines Agency (EMA). January 15, 2008. Archived from the original on October 22, 2020. Retrieved April 4, 2022.
"Enbrel EPAR". European Medicines Agency (EMA). September 11, 2009. Archived from the original on November 12, 2020. Retrieved March 7, 2024.
"Benepali EPAR". European Medicines Agency (EMA). January 28, 2016. Archived from the original on December 30, 2019. Retrieved April 4, 2022.
"Erelzi EPAR". European Medicines Agency (EMA). June 29, 2017. Archived from the original on December 30, 2019. Retrieved April 4, 2022.
"Lifmior EPAR". European Medicines Agency (EMA). March 13, 2017. Retrieved April 2, 2020.
"Nepexto EPAR". European Medicines Agency (EMA). March 24, 2020. Archived from the original on June 4, 2020. Retrieved June 4, 2020.
"Nivestim EPAR". European Medicines Agency (EMA). June 23, 2010. Archived from the original on December 20, 2019. Retrieved April 4, 2022.
"Accofil EPAR". European Medicines Agency (EMA). October 28, 2014. Archived from the original on March 23, 2020. Retrieved April 4, 2022.
"Biograstim EPAR". European Medicines Agency (EMA). September 17, 2018. Archived from the original on October 22, 2020. Retrieved April 2, 2020.
"Filgrastim Hexal EPAR". European Medicines Agency (EMA). February 16, 2009. Archived from the original on December 30, 2019. Retrieved April 4, 2022.
"Filgrastim ratiopharm EPAR". European Medicines Agency (EMA). September 17, 2018. Archived from the original on January 21, 2021. Retrieved April 2, 2020.
"Grastofil EPAR". European Medicines Agency (EMA). November 12, 2018. Archived from the original on November 12, 2020. Retrieved April 4, 2022.
"Ratiograstim EPAR". European Medicines Agency (EMA). September 29, 2009. Archived from the original on August 14, 2020. Retrieved April 4, 2022.
"Tevagrastim EPAR". European Medicines Agency (EMA). September 29, 2008. Archived from the original on October 16, 2019. Retrieved April 4, 2022.
"Zarzio EPAR". European Medicines Agency (EMA). February 17, 2009. Archived from the original on October 15, 2019. Retrieved April 4, 2022.
"Gonal-f EPAR". European Medicines Agency (EMA). October 20, 1995. Archived from the original on July 1, 2020. Retrieved March 7, 2024.
"Bemfola EPAR". European Medicines Agency (EMA). May 16, 2014. Archived from the original on October 28, 2020. Retrieved September 9, 2020.
"Ovaleap EPAR". European Medicines Agency (EMA). October 23, 2013. Archived from the original on September 23, 2020. Retrieved September 9, 2020.
"Remicade EPAR". European Medicines Agency (EMA). August 10, 2009. Archived from the original on October 22, 2020. Retrieved March 7, 2024.
"Flixabi EPAR". European Medicines Agency (EMA). June 9, 2016. Archived from the original on October 16, 2019. Retrieved April 4, 2022.
"Inflectra EPAR". European Medicines Agency (EMA). October 4, 2013. Archived from the original on October 16, 2019. Retrieved April 4, 2022.
"Remsima EPAR". European Medicines Agency (EMA). October 4, 2013. Archived from the original on December 29, 2019. Retrieved April 4, 2022.
"Zessly EPAR". European Medicines Agency (EMA). May 30, 2018. Archived from the original on December 30, 2019. Retrieved April 4, 2022.
"NovoRapid EPAR". European Medicines Agency (EMA). August 6, 2009. Archived from the original on September 22, 2023. Retrieved March 7, 2024.
"Fiasp EPAR". European Medicines Agency (EMA). February 3, 2017. Archived from the original on August 28, 2021. Retrieved August 27, 2021.
"Insulin aspart Sanofi EPAR". European Medicines Agency (EMA). April 28, 2020. Archived from the original on July 17, 2020. Retrieved September 9, 2020.
"Kirsty EPAR". European Medicines Agency (EMA). December 9, 2020. Archived from the original on September 15, 2021. Retrieved September 14, 2021.
"NovoMix EPAR". European Medicines Agency (EMA). October 4, 2007. Archived from the original on April 13, 2020. Retrieved August 27, 2021.
"Ryzodeg EPAR". European Medicines Agency (EMA). February 20, 2013. Archived from the original on August 28, 2021. Retrieved August 27, 2021.
"Lantus EPAR". European Medicines Agency (EMA). May 8, 2009. Archived from the original on August 4, 2020. Retrieved March 7, 2024.
"Abasaglar EPAR". European Medicines Agency (EMA). October 14, 2014. Archived from the original on April 2, 2022. Retrieved April 4, 2022.
"Semglee EPAR". European Medicines Agency (EMA). May 23, 2018. Archived from the original on February 15, 2022. Retrieved April 4, 2022.
"Humalog EPAR". European Medicines Agency (EMA). September 12, 2006. Archived from the original on February 24, 2020. Retrieved March 7, 2024.
"Insulin lispro Sanofi EPAR". European Medicines Agency (EMA). September 22, 2017. Archived from the original on February 24, 2020. Retrieved September 9, 2020.
"Neulasta EPAR". European Medicines Agency (EMA). June 19, 2009. Archived from the original on June 11, 2020. Retrieved April 2, 2020.
"Cegfila (previously Pegfilgrastim Mundipharma) EPAR". European Medicines Agency (EMA). October 16, 2019. Archived from the original on June 11, 2020. Retrieved April 2, 2020.
"Fulphila EPAR". European Medicines Agency (EMA). September 24, 2018. Archived from the original on June 11, 2020. Retrieved April 2, 2020.
"Grasustek EPAR". European Medicines Agency (EMA). April 24, 2019. Archived from the original on June 11, 2020. Retrieved April 2, 2020.
"Pelgraz EPAR". European Medicines Agency (EMA). October 26, 2018. Archived from the original on December 30, 2019. Retrieved April 2, 2020.
"Pelmeg EPAR". European Medicines Agency (EMA). September 24, 2018. Archived from the original on June 11, 2020. Retrieved April 2, 2020.
"Udenyca". European Medicines Agency (EMA. October 23, 2018. Archived from the original on June 11, 2020. Retrieved April 2, 2020.
"Stimufend EPAR". European Medicines Agency (EMA). January 24, 2022. Archived from the original on April 21, 2022. Retrieved April 4, 2022.
"Ziextenzo EPAR". European Medicines Agency (EMA). September 24, 2018. Archived from the original on June 11, 2020. Retrieved April 2, 2020.
"Lucentis EPAR". European Medicines Agency (EMA). December 12, 2008. Archived from the original on September 10, 2021. Retrieved September 9, 2021.
"Byooviz EPAR". European Medicines Agency (EMA). June 23, 2021. Archived from the original on September 10, 2021. Retrieved September 9, 2021.
"Ranivisio EPAR". European Medicines Agency (EMA). June 20, 2022. Archived from the original on October 6, 2022. Retrieved October 6, 2022.
"Ximluci EPAR". European Medicines Agency (EMA). September 14, 2022. Archived from the original on March 13, 2023. Retrieved March 3, 2023.
"MabThera EPAR". European Medicines Agency (EMA). October 30, 2009. Archived from the original on September 9, 2021. Retrieved September 8, 2021.
"Blitzima EPAR". European Medicines Agency (EMA). August 17, 2017. Archived from the original on September 9, 2021. Retrieved September 8, 2021.
"Ritemvia EPAR". European Medicines Agency (EMA). August 15, 2017. Archived from the original on September 9, 2021. Retrieved September 8, 2021.
"Rituzena EPAR". European Medicines Agency (EMA). Archived from the original on September 9, 2021. Retrieved September 8, 2021.
"Rixathon EPAR". European Medicines Agency (EMA). Archived from the original on September 9, 2021. Retrieved September 8, 2021.
"Riximyo EPAR". European Medicines Agency (EMA). July 28, 2017. Archived from the original on September 9, 2021. Retrieved September 8, 2021.
"Ruxience EPAR". European Medicines Agency (EMA). January 29, 2020. Archived from the original on September 9, 2021. Retrieved September 8, 2021.
"Truxima EPAR". European Medicines Agency (EMA). March 8, 2017. Archived from the original on September 9, 2021. Retrieved September 8, 2021.
"Omnitrope EPAR". European Medicines Agency (EMA). April 23, 2008. Archived from the original on July 27, 2020. Retrieved April 2, 2020.
"Forsteo EPAR". European Medicines Agency (EMA). March 27, 2009. Archived from the original on June 27, 2020. Retrieved March 7, 2024.
"Movymia EPAR". European Medicines Agency (EMA). March 16, 2017. Archived from the original on May 1, 2022. Retrieved April 4, 2022.
"Terrosa EPAR". European Medicines Agency (EMA). September 17, 2018. Archived from the original on August 14, 2019. Retrieved April 4, 2022.
"RoActemra EPAR". European Medicines Agency. January 16, 2009. Archived from the original on December 18, 2021. Retrieved March 7, 2024.
"Tyenne EPAR". European Medicines Agency (EMA). October 2, 2023. Archived from the original on October 5, 2023. Retrieved March 7, 2024.
"Herceptin EPAR". European Medicines Agency (EMA). Archived from the original on July 28, 2020. Retrieved July 28, 2020.
"Herzuma EPAR". European Medicines Agency (EMA). Archived from the original on November 8, 2020. Retrieved July 28, 2020.
"Kanjinti EPAR". European Medicines Agency (EMA). Archived from the original on October 31, 2020. Retrieved July 28, 2020.
"Ogivri EPAR". European Medicines Agency (EMA). Archived from the original on March 24, 2020. Retrieved July 28, 2020.
"Ontruzant EPAR". European Medicines Agency (EMA). Archived from the original on August 4, 2020. Retrieved July 28, 2020.
"Trazimera EPAR". European Medicines Agency (EMA). August 16, 2018. Archived from the original on July 28, 2020. Retrieved July 28, 2020.
"Zercepac EPAR". European Medicines Agency (EMA). May 26, 2020. Archived from the original on July 28, 2020. Retrieved July 28, 2020.

emea.europa.eu

EMEA guideline on similar biological medicinal products Archived June 30, 2007, at the Wayback Machine

fda.gov

accessdata.fda.gov

"Zarxio (filgrastim-sndz)". U.S. Food and Drug Administration (FDA). April 20, 2015. Archived from the original on December 20, 2019. Retrieved December 17, 2019.
"Inflectra (infliximab-dyyb) for Injection". U.S. Food and Drug Administration (FDA). June 27, 2016. Archived from the original on May 20, 2022. Retrieved November 26, 2023.
"Drug Approval Package: Erelzi (etanercept-szzs)". U.S. Food and Drug Administration (FDA). October 25, 2016. Archived from the original on December 5, 2022. Retrieved November 26, 2023.
"Drug Approval Package: Amjevita (adalimumab-atto)". U.S. Food and Drug Administration (FDA). November 9, 2016. Archived from the original on October 4, 2020. Retrieved November 26, 2023.
"Drug Approval Package: Renflexis (infliximab-abda)". U.S. Food and Drug Administration (FDA). December 10, 2018. Archived from the original on December 18, 2019. Retrieved December 17, 2019.
"Cyltezo: FDA Approved Drug Products". U.S. Food and Drug Administration (FDA). Archived from the original on February 18, 2020. Retrieved August 28, 2017.
"Drug Approval Package: Mvasi (bevacizumab-awwb)". U.S. Food and Drug Administration (FDA). October 10, 2018. Archived from the original on February 23, 2023. Retrieved November 26, 2023.
"Drug Approval Package: Ogivri (Trastuzumab-dkst)". U.S. Food and Drug Administration (FDA). November 29, 2018. Archived from the original on March 22, 2023. Retrieved November 26, 2023.
"Drug Approval Package: Ixifi (infliximab-qbtx)". U.S. Food and Drug Administration (FDA). November 29, 2018. Archived from the original on December 18, 2019. Retrieved December 17, 2019.
"Drug Approval Package: Retacrit (epoetin alfa-epbx )". U.S. Food and Drug Administration (FDA). December 13, 2018. Archived from the original on September 27, 2021. Retrieved November 26, 2023.
"Drug Approval Package: Fulphila". U.S. Food and Drug Administration (FDA). October 26, 2018. Archived from the original on June 11, 2020. Retrieved November 26, 2023.
"Drug Approval Package: Nivestym (filgrastim-aafi)". U.S. Food and Drug Administration (FDA). February 21, 2019. Archived from the original on December 20, 2019. Retrieved December 17, 2019.
"Drug Approval Package: Hyrimoz". U.S. Food and Drug Administration (FDA). March 21, 2019. Archived from the original on December 18, 2019. Retrieved December 17, 2019.
"Drug Approval Package: Udenyca". U.S. Food and Drug Administration (FDA). March 5, 2019. Archived from the original on December 18, 2019. Retrieved December 17, 2019.
"Drug Approval Package: Truxima (rituximab-abbs)". U.S. Food and Drug Administration (FDA). February 25, 2019. Archived from the original on December 18, 2019. Retrieved December 17, 2019.
"Drug Approval Package: Herzuma". U.S. Food and Drug Administration (FDA). February 7, 2019. Archived from the original on December 18, 2019. Retrieved December 17, 2019.
"Drug Approval Package: Ontruzant (trastuzumab-dttb)". U.S. Food and Drug Administration (FDA). March 5, 2019. Archived from the original on December 18, 2019. Retrieved December 17, 2019.
"Drug Approval Package: Trazimera (trastuzumab-qyyp)". U.S. Food and Drug Administration (FDA). May 17, 2019. Archived from the original on December 18, 2019. Retrieved December 17, 2019.
"Drug Approval Package: Eticovo". U.S. Food and Drug Administration (FDA). June 18, 2019. Archived from the original on December 18, 2019. Retrieved December 17, 2019.
"Drug Approval Package: Kanjinti". U.S. Food and Drug Administration (FDA). July 18, 2019. Archived from the original on December 18, 2019. Retrieved December 17, 2019.
"Drug Approval Package: Zirabev". U.S. Food and Drug Administration (FDA). August 14, 2019. Archived from the original on December 18, 2019. Retrieved December 17, 2019.
"Drug Approval Package: Ruxience". U.S. Food and Drug Administration (FDA). August 9, 2019. Archived from the original on December 18, 2019. Retrieved December 17, 2019.
"Drug Approval Package: Hadlima". U.S. Food and Drug Administration (FDA). September 5, 2019. Archived from the original on December 18, 2019. Retrieved December 17, 2019.
"Drug Approval Package: Ziextenzo". U.S. Food and Drug Administration (FDA). December 27, 2019. Archived from the original on June 11, 2020. Retrieved December 17, 2020.
"Drug Approval Package: Abrilada". U.S. Food and Drug Administration (FDA). January 28, 2020. Archived from the original on October 4, 2020. Retrieved December 17, 2020.
"Drug Approval Package: Avsola". U.S. Food and Drug Administration (FDA). January 30, 2020. Archived from the original on November 1, 2020. Retrieved December 17, 2020.
"Drug Approval Package: Nyvepria". U.S. Food and Drug Administration (FDA). August 11, 2020. Archived from the original on January 25, 2021. Retrieved December 17, 2020.
"Drug Approval Package: Hulio". U.S. Food and Drug Administration (FDA). October 2, 2020. Archived from the original on November 6, 2021. Retrieved December 17, 2020.
"Drug Approval Package: Riabni". U.S. Food and Drug Administration (FDA). January 26, 2021. Archived from the original on August 28, 2021. Retrieved August 28, 2021.
"Drug Approval Package: Semglee". U.S. Food and Drug Administration (FDA). September 2, 2021. Archived from the original on May 27, 2022. Retrieved May 26, 2022.
"Drug Approval Package: Byooviz". U.S. Food and Drug Administration (FDA). October 1, 2021. Archived from the original on January 25, 2023. Retrieved August 25, 2023.
"Drug Approval Package: Rezvoglar". U.S. Food and Drug Administration (FDA). January 28, 2022. Archived from the original on May 27, 2022. Retrieved May 26, 2022.
"Drug Approval Package: Yusimry". U.S. Food and Drug Administration (FDA). January 18, 2021. Archived from the original on May 27, 2022. Retrieved May 26, 2022.
"Drug Approval Package: Releuko". U.S. Food and Drug Administration (FDA). April 11, 2022. Archived from the original on May 27, 2022. Retrieved May 26, 2022.
"Drug Approval Package: Alymsys". U.S. Food and Drug Administration (FDA). May 11, 2022. Archived from the original on May 27, 2022. Retrieved May 27, 2022.
"Drug Approval Package: Fylnetra". U.S. Food and Drug Administration (FDA). July 15, 2022. Archived from the original on September 3, 2022. Retrieved August 25, 2023.
"Drug Approval Package: Cimerli". U.S. Food and Drug Administration (FDA). August 23, 2022. Archived from the original on September 29, 2022. Retrieved September 28, 2022.
"Drug Approval Package: Stimufend". U.S. Food and Drug Administration (FDA). November 16, 2022. Archived from the original on January 26, 2023. Retrieved August 25, 2023.
"Drug Approval Package: Vegzelma". U.S. Food and Drug Administration (FDA). December 13, 2022. Archived from the original on August 25, 2023. Retrieved August 25, 2023.
"Drug Approval Package: Idacio". U.S. Food and Drug Administration (FDA). February 9, 2023. Archived from the original on February 10, 2023. Retrieved August 25, 2023.
"Drug Approval Package: Yuflyma injection". U.S. Food and Drug Administration (FDA). August 11, 2023. Archived from the original on August 25, 2023. Retrieved August 25, 2023.
"Drug Approval Package: Tyruko". U.S. Food and Drug Administration (FDA). October 11, 2023. Archived from the original on November 26, 2023. Retrieved November 26, 2023.
"Drug Approval Package: Tofidence". U.S. Food and Drug Administration (FDA). November 7, 2023. Archived from the original on November 26, 2023. Retrieved November 26, 2023.

fda.gov

"FDA page on "Follow-On Protein Products: Regulatory and Scientific Issues Related to Developing"". U.S. Food and Drug Administration (FDA). Archived from the original on July 9, 2009.
"FDA page on "Approval Pathway for Biosimilar and Interchangeable Biological Products Public Meeting"". U.S. Food and Drug Administration (FDA). Archived from the original on October 7, 2010.
"FDA Response to three Citizen Petitions against biosimilars" (PDF). U.S. Food and Drug Administration (FDA). Archived from the original (PDF) on May 31, 2017. Retrieved December 16, 2019.
"FDA page on "FDA approves first biosimilar product Zarxio"". U.S. Food and Drug Administration (FDA). Archived from the original on March 7, 2015.
"Statement on low-cost biosimilar and interchangeable protein products". U.S. Food and Drug Administration (FDA). December 17, 2019. Archived from the original on December 18, 2019. Retrieved December 17, 2019. This article incorporates text from this source, which is in the public domain.
"Nonproprietary Naming of Biological Products; Draft Guidance for Industry; Availability". U.S. Food and Drug Administration (FDA). Archived from the original on September 6, 2019. Retrieved August 2, 2018.
Biosimilars, FDA, 2023, archived from the original on June 2, 2019, retrieved March 10, 2025
"Biosimilar Drug Information". U.S. Food and Drug Administration (FDA). Archived from the original on October 8, 2024. Retrieved October 8, 2024. This article incorporates text from this source, which is in the public domain.
"FDA Roundup: October 4, 2024". U.S. Food and Drug Administration (FDA) (Press release). October 4, 2024. Archived from the original on October 4, 2024. Retrieved October 8, 2024.
"Biosimilars". U.S. Food and Drug Administration. July 27, 2021. Archived from the original on August 28, 2021. Retrieved August 28, 2021. This article incorporates text from this source, which is in the public domain.
"Statement from FDA Commissioner Scott Gottlieb, M.D., on new actions advancing the agency's biosimilars policy framework". U.S. Food and Drug Administration (FDA) (Press release). December 11, 2018. Archived from the original on May 8, 2019. Retrieved December 16, 2018.
"FDA approves Erelzi, a biosimilar to Enbrel" (Press release). U.S. Food and Drug Administration (FDA). Archived from the original on August 28, 2021. Retrieved December 17, 2020.
"FDA approves Amjevita, a biosimilar to Humira" (Press release). U.S. Food and Drug Administration (FDA). Archived from the original on November 19, 2019. Retrieved December 17, 2020.
"FDA approves first biosimilar for the treatment of cancer" (Press release). U.S. Food and Drug Administration (FDA). Archived from the original on November 5, 2021. Retrieved December 17, 2020.
"FDA approves first biosimilar for the treatment of certain breast and stomach cancers" (Press release). U.S. Food and Drug Administration (FDA). Archived from the original on December 15, 2019. Retrieved December 17, 2020.
"FDA approves first epoetin alfa biosimilar for the treatment of anemia" (Press release). U.S. Food and Drug Administration (FDA). Archived from the original on August 28, 2021. Retrieved December 17, 2020.
"FDA approves first biosimilar to Neulasta to help reduce the risk of infection during cancer treatment" (Press release). U.S. Food and Drug Administration (FDA). Archived from the original on June 11, 2020. Retrieved December 17, 2020.
"FDA Approves Interchangeable Biosimilar for Multiple Inflammatory Diseases" (Press release). U.S. Food and Drug Administration (FDA). October 31, 2023. Archived from the original on November 13, 2023. Retrieved November 13, 2023.

gi.org

Epstein MS, Ehrenpreis ED, Kulkarni PM (December 2014). "Biosimilars: the need, the challenge, the future: the FDA perspective" (PDF). The American Journal of Gastroenterology. 109 (12): 1856–9. doi:10.1038/ajg.2014.151. PMID 24957160. S2CID 19274464. Archived from the original (PDF) on October 6, 2016. Retrieved September 25, 2016.

health.gov.au

www1.health.gov.au

"Which biosimilar medicines are available in Australia?". Archived from the original on December 30, 2021. Retrieved December 29, 2021.
"Which biosimilar medicines are available in Australia?". Archived from the original on December 30, 2021. Retrieved December 30, 2021.

house.gov

energycommerce.house.gov

Hearing: Assessing the Impact of a Safe and Equitable Biosimilar Policy in the United States. Subcommittee on Health Wednesday, May 2, 2007 Archived September 22, 2007, at the Wayback Machine

nih.gov

pubmed.ncbi.nlm.nih.gov

Lamanna WC, Holzmann J, Cohen HP, Guo X, Schweigler M, Stangler T, et al. (April 2018). "Maintaining consistent quality and clinical performance of biopharmaceuticals". Expert Opinion on Biological Therapy. 18 (4): 369–379. doi:10.1080/14712598.2018.1421169. PMID 29285958.
Warren JB (January 2013). "Generics, chemisimilars and biosimilars: is clinical testing fit for purpose?". British Journal of Clinical Pharmacology. 75 (1): 7–14. doi:10.1111/j.1365-2125.2012.04323.x. PMC 3555041. PMID 22574725.
Declerck PJ (February 2013). "Biosimilar monoclonal antibodies: a science-based regulatory challenge". Expert Opinion on Biological Therapy. 13 (2): 153–6. doi:10.1517/14712598.2012.758710. PMID 23286777.
Ivica, N. A., Young, C. M. (August 19, 2021). "Tracking the CAR-T Revolution: Analysis of Clinical Trials of CAR-T and TCR-T Therapies for the Treatment of Cancer (1997–2020)". Healthcare. 9 (8): 1062. doi:10.3390/healthcare9081062. ISSN 2227-9032. PMC 8392279. PMID 34442199.
Fasseeh AN, Elezbawy B, El-Fass KA, GamaI M, Seyam A, Hayek N, et al. (June 2023). "Maximizing the benefits of using biosimilars in Egypt". Journal of Pharmaceutical Policy and Practice. 16 (1): 79. doi:10.1186/s40545-023-00581-w. PMC 10291771. PMID 37365620.
Epstein MS, Ehrenpreis ED, Kulkarni PM (December 2014). "Biosimilars: the need, the challenge, the future: the FDA perspective" (PDF). The American Journal of Gastroenterology. 109 (12): 1856–9. doi:10.1038/ajg.2014.151. PMID 24957160. S2CID 19274464. Archived from the original (PDF) on October 6, 2016. Retrieved September 25, 2016.

ncbi.nlm.nih.gov

Warren JB (January 2013). "Generics, chemisimilars and biosimilars: is clinical testing fit for purpose?". British Journal of Clinical Pharmacology. 75 (1): 7–14. doi:10.1111/j.1365-2125.2012.04323.x. PMC 3555041. PMID 22574725.
Ivica, N. A., Young, C. M. (August 19, 2021). "Tracking the CAR-T Revolution: Analysis of Clinical Trials of CAR-T and TCR-T Therapies for the Treatment of Cancer (1997–2020)". Healthcare. 9 (8): 1062. doi:10.3390/healthcare9081062. ISSN 2227-9032. PMC 8392279. PMID 34442199.
Sharma, A., Kumar, N., Kuppermann, B. D., Francesco, B., Loewenstein, A. (July 2019). "Biologics, biosilimars, and biobetters: different terms or different drugs?". Eye. 33 (7): 1032–1034. doi:10.1038/s41433-019-0391-5. ISSN 0950-222X. PMC 6707288.
Fasseeh AN, Elezbawy B, El-Fass KA, GamaI M, Seyam A, Hayek N, et al. (June 2023). "Maximizing the benefits of using biosimilars in Egypt". Journal of Pharmaceutical Policy and Practice. 16 (1): 79. doi:10.1186/s40545-023-00581-w. PMC 10291771. PMID 37365620.

semanticscholar.org

api.semanticscholar.org

Nick, C (2012). "The US Biosimilars Act: Challenges Facing Regulatory Approval". Pharm Med. 26 (3): 145–152. doi:10.1007/bf03262388. S2CID 14604362.
Epstein MS, Ehrenpreis ED, Kulkarni PM (December 2014). "Biosimilars: the need, the challenge, the future: the FDA perspective" (PDF). The American Journal of Gastroenterology. 109 (12): 1856–9. doi:10.1038/ajg.2014.151. PMID 24957160. S2CID 19274464. Archived from the original (PDF) on October 6, 2016. Retrieved September 25, 2016.

senate.gov

judiciary.senate.gov

"US Senate Committee on the Judiciary, Testimony of Dr. Lester Crawford, Acting Commissioner, FDA June 23, 2004". Archived from the original on December 28, 2016. Retrieved October 8, 2007.

southcentre.int

Velásquez G (August 2018). "The International Debate on Generic Medicines of Biological Origin" (PDF). South Centre Policy Brief (50). Archived (PDF) from the original on March 6, 2021. Retrieved December 23, 2020.

tga.gov.au

"Biosimilar medicines regulation". Therapeutic Goods Administration (TGA). April 4, 2018. Archived from the original on December 30, 2021. Retrieved December 29, 2021.

web.archive.org

"Biosimilars in the EU: Information guide for healthcare professionals" (PDF). European Medicines Agency and the European Commission. 2017. Archived from the original (PDF) on October 15, 2019.
Guidelines on evaluation of similar Biotherapeutic Products (SBPs) (PDF) (Report). World Health Organization (WHO). 2009. Archived from the original (PDF) on September 29, 2021. Retrieved October 24, 2019.
Guidelines on evaluation of similar Biotherapeutic Products (SBPs), Annex 2, Technical Report Series No. 977 (PDF) (Report). World Health Organization (WHO). 2013. Archived (PDF) from the original on May 30, 2015. Retrieved December 18, 2019.
WHO Questions and Answers: Similar Biotherapeutic Products (PDF) (Report). World Health Organization (WHO). 2018. Archived (PDF) from the original on April 21, 2019. Retrieved December 18, 2019.
Guidelines on evaluation of monoclonal antibodies (mAbs) as similar biotherapeutic products (SBPs), Annex 2, Technical Report Series No. 1004 (PDF) (Report). World Health Organization (WHO). 2017. Archived (PDF) from the original on April 14, 2021. Retrieved December 18, 2019.
"Biosimilar medicines: Overview". European Medicines Agency (EMA). September 17, 2018. Archived from the original on March 29, 2020. Retrieved April 21, 2020.
"US Senate Committee on the Judiciary, Testimony of Dr. Lester Crawford, Acting Commissioner, FDA June 23, 2004". Archived from the original on December 28, 2016. Retrieved October 8, 2007.
Hearing: Assessing the Impact of a Safe and Equitable Biosimilar Policy in the United States. Subcommittee on Health Wednesday, May 2, 2007 Archived September 22, 2007, at the Wayback Machine
"FDA page on "Follow-On Protein Products: Regulatory and Scientific Issues Related to Developing"". U.S. Food and Drug Administration (FDA). Archived from the original on July 9, 2009.
"FDA page on "Approval Pathway for Biosimilar and Interchangeable Biological Products Public Meeting"". U.S. Food and Drug Administration (FDA). Archived from the original on October 7, 2010.
"FDA Response to three Citizen Petitions against biosimilars" (PDF). U.S. Food and Drug Administration (FDA). Archived from the original (PDF) on May 31, 2017. Retrieved December 16, 2019.
"FDA page on "FDA approves first biosimilar product Zarxio"". U.S. Food and Drug Administration (FDA). Archived from the original on March 7, 2015.
"Statement on low-cost biosimilar and interchangeable protein products". U.S. Food and Drug Administration (FDA). December 17, 2019. Archived from the original on December 18, 2019. Retrieved December 17, 2019. This article incorporates text from this source, which is in the public domain.
EMEA guideline on similar biological medicinal products Archived June 30, 2007, at the Wayback Machine
Wang X (June 1, 2014). "Higher-Order Structure Comparability: Case Studies of Biosimilar Monoclonal Antibodies". BioProcess International. 12 (6): 32–37. Archived from the original on January 19, 2021. Retrieved August 13, 2014.
"Nonproprietary Naming of Biological Products; Draft Guidance for Industry; Availability". U.S. Food and Drug Administration (FDA). Archived from the original on September 6, 2019. Retrieved August 2, 2018.
Velásquez G (August 2018). "The International Debate on Generic Medicines of Biological Origin" (PDF). South Centre Policy Brief (50). Archived (PDF) from the original on March 6, 2021. Retrieved December 23, 2020.
"Australian Government Announces Decision on Biosimilar Naming Conventions". The Center For Biosimilars. January 31, 2018. Archived from the original on December 30, 2021. Retrieved December 20, 2021.
"Biosimilar medicines regulation". Therapeutic Goods Administration (TGA). April 4, 2018. Archived from the original on December 30, 2021. Retrieved December 29, 2021.
"Which biosimilar medicines are available in Australia?". Archived from the original on December 30, 2021. Retrieved December 29, 2021.
"Biological Qualifier". WHO. Archived from the original on March 28, 2015.
"WHO Report on the Expert Consultation on Improving Access to and Use of Similar Biotherapeutic Products" (PDF). Archived (PDF) from the original on October 31, 2017. Retrieved August 2, 2019.
Biosimilars, FDA, 2023, archived from the original on June 2, 2019, retrieved March 10, 2025
"Which biosimilar medicines are available in Australia?". Archived from the original on December 30, 2021. Retrieved December 30, 2021.
"Biosimilar medicines can be interchanged". European Medicines Agency (EMA) (Press release). September 19, 2022. Archived from the original on September 20, 2022. Retrieved September 19, 2022.
"EU Approved biosimilars by molecule [data arranged from EMA website]" (PDF). Biosimilars Nederland. Archived (PDF) from the original on September 19, 2020. Retrieved June 9, 2020.
"Humira EPAR". European Medicines Agency (EMA). November 24, 2009. Archived from the original on February 18, 2020. Retrieved March 7, 2024.
"Amgevita EPAR". European Medicines Agency (EMA). April 6, 2017. Archived from the original on December 30, 2019. Retrieved April 21, 2020.
"Amsparity EPAR". European Medicines Agency (EMA). December 9, 2019. Archived from the original on February 18, 2020. Retrieved April 21, 2020.
"Cyltezo EPAR". European Medicines Agency (EMA). November 17, 2017. Archived from the original on August 6, 2020. Retrieved August 27, 2021.
"Halimatoz EPAR". European Medicines Agency (EMA). August 3, 2018. Archived from the original on December 30, 2019. Retrieved April 21, 2020.
"Hefiya EPAR". European Medicines Agency (EMA). August 6, 2018. Archived from the original on October 15, 2019. Retrieved April 21, 2020.
"Hukyndra EPAR". European Medicines Agency (EMA). September 14, 2021. Archived from the original on April 24, 2022. Retrieved April 23, 2022.
"Hulio EPAR". European Medicines Agency (EMA). September 21, 2018. Archived from the original on March 24, 2020. Retrieved April 21, 2020.
"Hyrimoz EPAR". European Medicines Agency (EMA). August 2, 2018. Archived from the original on November 16, 2019. Retrieved April 21, 2020.
"Idacio EPAR". European Medicines Agency (EMA). January 29, 2019. Archived from the original on December 30, 2019. Retrieved April 21, 2020.
"Imraldi EPAR". European Medicines Agency (EMA). August 31, 2017. Archived from the original on March 24, 2020. Retrieved April 21, 2020.
"Kromeya EPAR". European Medicines Agency (EMA). January 29, 2019. Archived from the original on December 30, 2019. Retrieved August 27, 2021.
"Libmyris EPAR". European Medicines Agency (EMA). September 14, 2021. Archived from the original on April 24, 2022. Retrieved April 23, 2022.
"Solymbic EPAR". European Medicines Agency (EMA). April 7, 2017. Archived from the original on June 25, 2019. Retrieved August 27, 2021.
"Trudexa EPAR". European Medicines Agency (EMA). February 15, 2008. Archived from the original on February 18, 2020. Retrieved August 27, 2021.
"Yuflyma EPAR". European Medicines Agency (EMA). December 9, 2020. Archived from the original on August 28, 2021. Retrieved August 27, 2021.
"Avastin EPAR". European Medicines Agency (EMA). September 17, 2009. Archived from the original on March 18, 2020. Retrieved September 11, 2021.
"Abevmy EPAR". European Medicines Agency (EMA). February 24, 2021. Archived from the original on August 28, 2021. Retrieved August 27, 2021.
"Alymsys EPAR". European Medicines Agency (EMA). January 25, 2021. Archived from the original on October 8, 2021. Retrieved September 11, 2021.
"Aybintio EPAR". European Medicines Agency (EMA). May 26, 2020. Archived from the original on December 29, 2020. Retrieved September 9, 2020.
"Equidacent EPAR". European Medicines Agency (EMA). July 20, 2020. Archived from the original on October 13, 2020. Retrieved October 12, 2020.
"Mvasi EPAR". European Medicines Agency (EMA). January 31, 2018. Archived from the original on December 30, 2019. Retrieved April 2, 2020.
"Onbevzi EPAR". European Medicines Agency (EMA). November 9, 2020. Archived from the original on November 5, 2021. Retrieved September 11, 2021.
"Oyavas EPAR". European Medicines Agency (EMA). January 25, 2021. Archived from the original on October 8, 2021. Retrieved September 11, 2021.
"Vegzelma EPAR". European Medicines Agency (EMA). June 20, 2022. Archived from the original on January 28, 2023. Retrieved March 3, 2023.
"Zirabev EPAR". European Medicines Agency (EMA). December 11, 2018. Archived from the original on December 30, 2019. Retrieved April 2, 2020.
"Inhixa EPAR". European Medicines Agency (EMA). October 26, 2016. Archived from the original on October 29, 2020. Retrieved September 9, 2020.
"Thorinane EPAR". European Medicines Agency (EMA). October 26, 2016. Archived from the original on December 30, 2019. Retrieved April 2, 2020.
"Abseamed EPAR". European Medicines Agency (EMA). February 6, 2009. Archived from the original on March 23, 2020. Retrieved April 4, 2022.
"Binocrit EPAR". European Medicines Agency (EMA). October 12, 2009. Archived from the original on December 30, 2019. Retrieved April 4, 2022.
"Epoetin Alfa Hexal EPAR". European Medicines Agency (EMA). October 12, 2009. Archived from the original on December 30, 2019. Retrieved April 4, 2022.
"Retacrit EPAR". European Medicines Agency (EMA). January 15, 2008. Archived from the original on December 30, 2019. Retrieved April 4, 2022.
"Silapo EPAR". European Medicines Agency (EMA). January 15, 2008. Archived from the original on October 22, 2020. Retrieved April 4, 2022.
"Enbrel EPAR". European Medicines Agency (EMA). September 11, 2009. Archived from the original on November 12, 2020. Retrieved March 7, 2024.
"Benepali EPAR". European Medicines Agency (EMA). January 28, 2016. Archived from the original on December 30, 2019. Retrieved April 4, 2022.
"Erelzi EPAR". European Medicines Agency (EMA). June 29, 2017. Archived from the original on December 30, 2019. Retrieved April 4, 2022.
"Nepexto EPAR". European Medicines Agency (EMA). March 24, 2020. Archived from the original on June 4, 2020. Retrieved June 4, 2020.
"Nivestim EPAR". European Medicines Agency (EMA). June 23, 2010. Archived from the original on December 20, 2019. Retrieved April 4, 2022.
"Accofil EPAR". European Medicines Agency (EMA). October 28, 2014. Archived from the original on March 23, 2020. Retrieved April 4, 2022.
"Biograstim EPAR". European Medicines Agency (EMA). September 17, 2018. Archived from the original on October 22, 2020. Retrieved April 2, 2020.
"Filgrastim Hexal EPAR". European Medicines Agency (EMA). February 16, 2009. Archived from the original on December 30, 2019. Retrieved April 4, 2022.
"Filgrastim ratiopharm EPAR". European Medicines Agency (EMA). September 17, 2018. Archived from the original on January 21, 2021. Retrieved April 2, 2020.
"Grastofil EPAR". European Medicines Agency (EMA). November 12, 2018. Archived from the original on November 12, 2020. Retrieved April 4, 2022.
"Ratiograstim EPAR". European Medicines Agency (EMA). September 29, 2009. Archived from the original on August 14, 2020. Retrieved April 4, 2022.
"Tevagrastim EPAR". European Medicines Agency (EMA). September 29, 2008. Archived from the original on October 16, 2019. Retrieved April 4, 2022.
"Zarzio EPAR". European Medicines Agency (EMA). February 17, 2009. Archived from the original on October 15, 2019. Retrieved April 4, 2022.
"Gonal-f EPAR". European Medicines Agency (EMA). October 20, 1995. Archived from the original on July 1, 2020. Retrieved March 7, 2024.
"Bemfola EPAR". European Medicines Agency (EMA). May 16, 2014. Archived from the original on October 28, 2020. Retrieved September 9, 2020.
"Ovaleap EPAR". European Medicines Agency (EMA). October 23, 2013. Archived from the original on September 23, 2020. Retrieved September 9, 2020.
"Remicade EPAR". European Medicines Agency (EMA). August 10, 2009. Archived from the original on October 22, 2020. Retrieved March 7, 2024.
"Flixabi EPAR". European Medicines Agency (EMA). June 9, 2016. Archived from the original on October 16, 2019. Retrieved April 4, 2022.
"Inflectra EPAR". European Medicines Agency (EMA). October 4, 2013. Archived from the original on October 16, 2019. Retrieved April 4, 2022.
"Remsima EPAR". European Medicines Agency (EMA). October 4, 2013. Archived from the original on December 29, 2019. Retrieved April 4, 2022.
"Zessly EPAR". European Medicines Agency (EMA). May 30, 2018. Archived from the original on December 30, 2019. Retrieved April 4, 2022.
"NovoRapid EPAR". European Medicines Agency (EMA). August 6, 2009. Archived from the original on September 22, 2023. Retrieved March 7, 2024.
"Fiasp EPAR". European Medicines Agency (EMA). February 3, 2017. Archived from the original on August 28, 2021. Retrieved August 27, 2021.
"Insulin aspart Sanofi EPAR". European Medicines Agency (EMA). April 28, 2020. Archived from the original on July 17, 2020. Retrieved September 9, 2020.
"Kirsty EPAR". European Medicines Agency (EMA). December 9, 2020. Archived from the original on September 15, 2021. Retrieved September 14, 2021.
"NovoMix EPAR". European Medicines Agency (EMA). October 4, 2007. Archived from the original on April 13, 2020. Retrieved August 27, 2021.
"Ryzodeg EPAR". European Medicines Agency (EMA). February 20, 2013. Archived from the original on August 28, 2021. Retrieved August 27, 2021.
"Lantus EPAR". European Medicines Agency (EMA). May 8, 2009. Archived from the original on August 4, 2020. Retrieved March 7, 2024.
"Abasaglar EPAR". European Medicines Agency (EMA). October 14, 2014. Archived from the original on April 2, 2022. Retrieved April 4, 2022.
"Semglee EPAR". European Medicines Agency (EMA). May 23, 2018. Archived from the original on February 15, 2022. Retrieved April 4, 2022.
"Humalog EPAR". European Medicines Agency (EMA). September 12, 2006. Archived from the original on February 24, 2020. Retrieved March 7, 2024.
"Insulin lispro Sanofi EPAR". European Medicines Agency (EMA). September 22, 2017. Archived from the original on February 24, 2020. Retrieved September 9, 2020.
"Neulasta EPAR". European Medicines Agency (EMA). June 19, 2009. Archived from the original on June 11, 2020. Retrieved April 2, 2020.
"Cegfila (previously Pegfilgrastim Mundipharma) EPAR". European Medicines Agency (EMA). October 16, 2019. Archived from the original on June 11, 2020. Retrieved April 2, 2020.
"Fulphila EPAR". European Medicines Agency (EMA). September 24, 2018. Archived from the original on June 11, 2020. Retrieved April 2, 2020.
"Grasustek EPAR". European Medicines Agency (EMA). April 24, 2019. Archived from the original on June 11, 2020. Retrieved April 2, 2020.
"Pelgraz EPAR". European Medicines Agency (EMA). October 26, 2018. Archived from the original on December 30, 2019. Retrieved April 2, 2020.
"Pelmeg EPAR". European Medicines Agency (EMA). September 24, 2018. Archived from the original on June 11, 2020. Retrieved April 2, 2020.
"Udenyca". European Medicines Agency (EMA. October 23, 2018. Archived from the original on June 11, 2020. Retrieved April 2, 2020.
"Stimufend EPAR". European Medicines Agency (EMA). January 24, 2022. Archived from the original on April 21, 2022. Retrieved April 4, 2022.
"Ziextenzo EPAR". European Medicines Agency (EMA). September 24, 2018. Archived from the original on June 11, 2020. Retrieved April 2, 2020.
"Lucentis EPAR". European Medicines Agency (EMA). December 12, 2008. Archived from the original on September 10, 2021. Retrieved September 9, 2021.
"Byooviz EPAR". European Medicines Agency (EMA). June 23, 2021. Archived from the original on September 10, 2021. Retrieved September 9, 2021.
"Ranivisio EPAR". European Medicines Agency (EMA). June 20, 2022. Archived from the original on October 6, 2022. Retrieved October 6, 2022.
"Ximluci EPAR". European Medicines Agency (EMA). September 14, 2022. Archived from the original on March 13, 2023. Retrieved March 3, 2023.
"MabThera EPAR". European Medicines Agency (EMA). October 30, 2009. Archived from the original on September 9, 2021. Retrieved September 8, 2021.
"Blitzima EPAR". European Medicines Agency (EMA). August 17, 2017. Archived from the original on September 9, 2021. Retrieved September 8, 2021.
"Ritemvia EPAR". European Medicines Agency (EMA). August 15, 2017. Archived from the original on September 9, 2021. Retrieved September 8, 2021.
"Rituzena EPAR". European Medicines Agency (EMA). Archived from the original on September 9, 2021. Retrieved September 8, 2021.
"Rixathon EPAR". European Medicines Agency (EMA). Archived from the original on September 9, 2021. Retrieved September 8, 2021.
"Riximyo EPAR". European Medicines Agency (EMA). July 28, 2017. Archived from the original on September 9, 2021. Retrieved September 8, 2021.
"Ruxience EPAR". European Medicines Agency (EMA). January 29, 2020. Archived from the original on September 9, 2021. Retrieved September 8, 2021.
"Truxima EPAR". European Medicines Agency (EMA). March 8, 2017. Archived from the original on September 9, 2021. Retrieved September 8, 2021.
"Omnitrope EPAR". European Medicines Agency (EMA). April 23, 2008. Archived from the original on July 27, 2020. Retrieved April 2, 2020.
"Forsteo EPAR". European Medicines Agency (EMA). March 27, 2009. Archived from the original on June 27, 2020. Retrieved March 7, 2024.
"Movymia EPAR". European Medicines Agency (EMA). March 16, 2017. Archived from the original on May 1, 2022. Retrieved April 4, 2022.
"Terrosa EPAR". European Medicines Agency (EMA). September 17, 2018. Archived from the original on August 14, 2019. Retrieved April 4, 2022.
"RoActemra EPAR". European Medicines Agency. January 16, 2009. Archived from the original on December 18, 2021. Retrieved March 7, 2024.
"Tyenne EPAR". European Medicines Agency (EMA). October 2, 2023. Archived from the original on October 5, 2023. Retrieved March 7, 2024.
"Herceptin EPAR". European Medicines Agency (EMA). Archived from the original on July 28, 2020. Retrieved July 28, 2020.
"Herzuma EPAR". European Medicines Agency (EMA). Archived from the original on November 8, 2020. Retrieved July 28, 2020.
"Kanjinti EPAR". European Medicines Agency (EMA). Archived from the original on October 31, 2020. Retrieved July 28, 2020.
"Ogivri EPAR". European Medicines Agency (EMA). Archived from the original on March 24, 2020. Retrieved July 28, 2020.
"Ontruzant EPAR". European Medicines Agency (EMA). Archived from the original on August 4, 2020. Retrieved July 28, 2020.
"Trazimera EPAR". European Medicines Agency (EMA). August 16, 2018. Archived from the original on July 28, 2020. Retrieved July 28, 2020.
"Zercepac EPAR". European Medicines Agency (EMA). May 26, 2020. Archived from the original on July 28, 2020. Retrieved July 28, 2020.
"Biosimilar Drug Information". U.S. Food and Drug Administration (FDA). Archived from the original on October 8, 2024. Retrieved October 8, 2024. This article incorporates text from this source, which is in the public domain.
"FDA Roundup: October 4, 2024". U.S. Food and Drug Administration (FDA) (Press release). October 4, 2024. Archived from the original on October 4, 2024. Retrieved October 8, 2024.
"Biosimilars". U.S. Food and Drug Administration. July 27, 2021. Archived from the original on August 28, 2021. Retrieved August 28, 2021. This article incorporates text from this source, which is in the public domain.
Epstein MS, Ehrenpreis ED, Kulkarni PM (December 2014). "Biosimilars: the need, the challenge, the future: the FDA perspective" (PDF). The American Journal of Gastroenterology. 109 (12): 1856–9. doi:10.1038/ajg.2014.151. PMID 24957160. S2CID 19274464. Archived from the original (PDF) on October 6, 2016. Retrieved September 25, 2016.
"Statement from FDA Commissioner Scott Gottlieb, M.D., on new actions advancing the agency's biosimilars policy framework". U.S. Food and Drug Administration (FDA) (Press release). December 11, 2018. Archived from the original on May 8, 2019. Retrieved December 16, 2018.
"Zarxio (filgrastim-sndz)". U.S. Food and Drug Administration (FDA). April 20, 2015. Archived from the original on December 20, 2019. Retrieved December 17, 2019.
"Inflectra (infliximab-dyyb) for Injection". U.S. Food and Drug Administration (FDA). June 27, 2016. Archived from the original on May 20, 2022. Retrieved November 26, 2023.
"FDA approves Erelzi, a biosimilar to Enbrel" (Press release). U.S. Food and Drug Administration (FDA). Archived from the original on August 28, 2021. Retrieved December 17, 2020.
"Drug Approval Package: Erelzi (etanercept-szzs)". U.S. Food and Drug Administration (FDA). October 25, 2016. Archived from the original on December 5, 2022. Retrieved November 26, 2023.
"FDA approves Amjevita, a biosimilar to Humira" (Press release). U.S. Food and Drug Administration (FDA). Archived from the original on November 19, 2019. Retrieved December 17, 2020.
"Drug Approval Package: Amjevita (adalimumab-atto)". U.S. Food and Drug Administration (FDA). November 9, 2016. Archived from the original on October 4, 2020. Retrieved November 26, 2023.
"Drug Approval Package: Renflexis (infliximab-abda)". U.S. Food and Drug Administration (FDA). December 10, 2018. Archived from the original on December 18, 2019. Retrieved December 17, 2019.
"Cyltezo: FDA Approved Drug Products". U.S. Food and Drug Administration (FDA). Archived from the original on February 18, 2020. Retrieved August 28, 2017.
"FDA approves first biosimilar for the treatment of cancer" (Press release). U.S. Food and Drug Administration (FDA). Archived from the original on November 5, 2021. Retrieved December 17, 2020.
"Drug Approval Package: Mvasi (bevacizumab-awwb)". U.S. Food and Drug Administration (FDA). October 10, 2018. Archived from the original on February 23, 2023. Retrieved November 26, 2023.
"FDA approves first biosimilar for the treatment of certain breast and stomach cancers" (Press release). U.S. Food and Drug Administration (FDA). Archived from the original on December 15, 2019. Retrieved December 17, 2020.
"Drug Approval Package: Ogivri (Trastuzumab-dkst)". U.S. Food and Drug Administration (FDA). November 29, 2018. Archived from the original on March 22, 2023. Retrieved November 26, 2023.
"Drug Approval Package: Ixifi (infliximab-qbtx)". U.S. Food and Drug Administration (FDA). November 29, 2018. Archived from the original on December 18, 2019. Retrieved December 17, 2019.
"FDA approves first epoetin alfa biosimilar for the treatment of anemia" (Press release). U.S. Food and Drug Administration (FDA). Archived from the original on August 28, 2021. Retrieved December 17, 2020.
"Drug Approval Package: Retacrit (epoetin alfa-epbx )". U.S. Food and Drug Administration (FDA). December 13, 2018. Archived from the original on September 27, 2021. Retrieved November 26, 2023.
"FDA approves first biosimilar to Neulasta to help reduce the risk of infection during cancer treatment" (Press release). U.S. Food and Drug Administration (FDA). Archived from the original on June 11, 2020. Retrieved December 17, 2020.
"Drug Approval Package: Fulphila". U.S. Food and Drug Administration (FDA). October 26, 2018. Archived from the original on June 11, 2020. Retrieved November 26, 2023.
"Drug Approval Package: Nivestym (filgrastim-aafi)". U.S. Food and Drug Administration (FDA). February 21, 2019. Archived from the original on December 20, 2019. Retrieved December 17, 2019.
"Drug Approval Package: Hyrimoz". U.S. Food and Drug Administration (FDA). March 21, 2019. Archived from the original on December 18, 2019. Retrieved December 17, 2019.
"Drug Approval Package: Udenyca". U.S. Food and Drug Administration (FDA). March 5, 2019. Archived from the original on December 18, 2019. Retrieved December 17, 2019.
"Drug Approval Package: Truxima (rituximab-abbs)". U.S. Food and Drug Administration (FDA). February 25, 2019. Archived from the original on December 18, 2019. Retrieved December 17, 2019.
"Drug Approval Package: Herzuma". U.S. Food and Drug Administration (FDA). February 7, 2019. Archived from the original on December 18, 2019. Retrieved December 17, 2019.
"Drug Approval Package: Ontruzant (trastuzumab-dttb)". U.S. Food and Drug Administration (FDA). March 5, 2019. Archived from the original on December 18, 2019. Retrieved December 17, 2019.
"Drug Approval Package: Trazimera (trastuzumab-qyyp)". U.S. Food and Drug Administration (FDA). May 17, 2019. Archived from the original on December 18, 2019. Retrieved December 17, 2019.
"Drug Approval Package: Eticovo". U.S. Food and Drug Administration (FDA). June 18, 2019. Archived from the original on December 18, 2019. Retrieved December 17, 2019.
"Drug Approval Package: Kanjinti". U.S. Food and Drug Administration (FDA). July 18, 2019. Archived from the original on December 18, 2019. Retrieved December 17, 2019.
"Drug Approval Package: Zirabev". U.S. Food and Drug Administration (FDA). August 14, 2019. Archived from the original on December 18, 2019. Retrieved December 17, 2019.
"Drug Approval Package: Ruxience". U.S. Food and Drug Administration (FDA). August 9, 2019. Archived from the original on December 18, 2019. Retrieved December 17, 2019.
"Drug Approval Package: Hadlima". U.S. Food and Drug Administration (FDA). September 5, 2019. Archived from the original on December 18, 2019. Retrieved December 17, 2019.
"Drug Approval Package: Ziextenzo". U.S. Food and Drug Administration (FDA). December 27, 2019. Archived from the original on June 11, 2020. Retrieved December 17, 2020.
"Drug Approval Package: Abrilada". U.S. Food and Drug Administration (FDA). January 28, 2020. Archived from the original on October 4, 2020. Retrieved December 17, 2020.
"Drug Approval Package: Avsola". U.S. Food and Drug Administration (FDA). January 30, 2020. Archived from the original on November 1, 2020. Retrieved December 17, 2020.
"Drug Approval Package: Nyvepria". U.S. Food and Drug Administration (FDA). August 11, 2020. Archived from the original on January 25, 2021. Retrieved December 17, 2020.
"Drug Approval Package: Hulio". U.S. Food and Drug Administration (FDA). October 2, 2020. Archived from the original on November 6, 2021. Retrieved December 17, 2020.
"Drug Approval Package: Riabni". U.S. Food and Drug Administration (FDA). January 26, 2021. Archived from the original on August 28, 2021. Retrieved August 28, 2021.
"Drug Approval Package: Semglee". U.S. Food and Drug Administration (FDA). September 2, 2021. Archived from the original on May 27, 2022. Retrieved May 26, 2022.
"Drug Approval Package: Byooviz". U.S. Food and Drug Administration (FDA). October 1, 2021. Archived from the original on January 25, 2023. Retrieved August 25, 2023.
"Drug Approval Package: Rezvoglar". U.S. Food and Drug Administration (FDA). January 28, 2022. Archived from the original on May 27, 2022. Retrieved May 26, 2022.
"Drug Approval Package: Yusimry". U.S. Food and Drug Administration (FDA). January 18, 2021. Archived from the original on May 27, 2022. Retrieved May 26, 2022.
"Drug Approval Package: Releuko". U.S. Food and Drug Administration (FDA). April 11, 2022. Archived from the original on May 27, 2022. Retrieved May 26, 2022.
"Drug Approval Package: Alymsys". U.S. Food and Drug Administration (FDA). May 11, 2022. Archived from the original on May 27, 2022. Retrieved May 27, 2022.
"Drug Approval Package: Fylnetra". U.S. Food and Drug Administration (FDA). July 15, 2022. Archived from the original on September 3, 2022. Retrieved August 25, 2023.
"Drug Approval Package: Cimerli". U.S. Food and Drug Administration (FDA). August 23, 2022. Archived from the original on September 29, 2022. Retrieved September 28, 2022.
"Drug Approval Package: Stimufend". U.S. Food and Drug Administration (FDA). November 16, 2022. Archived from the original on January 26, 2023. Retrieved August 25, 2023.
"Drug Approval Package: Vegzelma". U.S. Food and Drug Administration (FDA). December 13, 2022. Archived from the original on August 25, 2023. Retrieved August 25, 2023.
"Drug Approval Package: Idacio". U.S. Food and Drug Administration (FDA). February 9, 2023. Archived from the original on February 10, 2023. Retrieved August 25, 2023.
"Drug Approval Package: Yuflyma injection". U.S. Food and Drug Administration (FDA). August 11, 2023. Archived from the original on August 25, 2023. Retrieved August 25, 2023.
"Drug Approval Package: Tyruko". U.S. Food and Drug Administration (FDA). October 11, 2023. Archived from the original on November 26, 2023. Retrieved November 26, 2023.
"Drug Approval Package: Tofidence". U.S. Food and Drug Administration (FDA). November 7, 2023. Archived from the original on November 26, 2023. Retrieved November 26, 2023.
"FDA Approves Interchangeable Biosimilar for Multiple Inflammatory Diseases" (Press release). U.S. Food and Drug Administration (FDA). October 31, 2023. Archived from the original on November 13, 2023. Retrieved November 13, 2023.

who.int

Guidelines on evaluation of similar Biotherapeutic Products (SBPs) (PDF) (Report). World Health Organization (WHO). 2009. Archived from the original (PDF) on September 29, 2021. Retrieved October 24, 2019.
Guidelines on evaluation of similar Biotherapeutic Products (SBPs), Annex 2, Technical Report Series No. 977 (PDF) (Report). World Health Organization (WHO). 2013. Archived (PDF) from the original on May 30, 2015. Retrieved December 18, 2019.
WHO Questions and Answers: Similar Biotherapeutic Products (PDF) (Report). World Health Organization (WHO). 2018. Archived (PDF) from the original on April 21, 2019. Retrieved December 18, 2019.
Guidelines on evaluation of monoclonal antibodies (mAbs) as similar biotherapeutic products (SBPs), Annex 2, Technical Report Series No. 1004 (PDF) (Report). World Health Organization (WHO). 2017. Archived (PDF) from the original on April 14, 2021. Retrieved December 18, 2019.
"Biological Qualifier". WHO. Archived from the original on March 28, 2015.
"WHO Report on the Expert Consultation on Improving Access to and Use of Similar Biotherapeutic Products" (PDF). Archived (PDF) from the original on October 31, 2017. Retrieved August 2, 2019.

worldcat.org

search.worldcat.org

Ivica, N. A., Young, C. M. (August 19, 2021). "Tracking the CAR-T Revolution: Analysis of Clinical Trials of CAR-T and TCR-T Therapies for the Treatment of Cancer (1997–2020)". Healthcare. 9 (8): 1062. doi:10.3390/healthcare9081062. ISSN 2227-9032. PMC 8392279. PMID 34442199.
Sharma, A., Kumar, N., Kuppermann, B. D., Francesco, B., Loewenstein, A. (July 2019). "Biologics, biosilimars, and biobetters: different terms or different drugs?". Eye. 33 (7): 1032–1034. doi:10.1038/s41433-019-0391-5. ISSN 0950-222X. PMC 6707288.